FDA’s Botched Review of Moderna’s Flu mRNA Vaccine
When the FDA licensed Moderna’s new mRNA flu vaccine [earlier this month], legacy media coverage focused almost exclusively on efficacy. The pivotal trial reported that the vaccine was “26.6% more effective” than a conventional flu vaccine at preventing protocol-defined influenza-like illness. What received far less scrutiny was a much more serious problem in the trial […]